Drug intelligence / Profile preview

QBSAU

Development stage: Preclinical
Lead developer: Qu Biologics
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Subcutaneous

Overview

QBSAU is an investigative Site Specific Immunomodulator (SSI) being developed by Qu Biologics for the treatment of melanoma and breast cancer. Derived from inactivated *Staphylococcus aureus*, QBSAU is part of a novel class of immunotherapies designed to restore and 'train' innate immune function in targeted organs. The SSI platform operates on the principle that specific bacterial species can stimulate an immune response in the organs they typically infect; as *S. aureus* is commonly associated with skin and bone, QBSAU is designed to modulate the immune environment in these tissues. The drug is administered subcutaneously and aims to reverse the immune dysregulation that allows cancer cells to evade detection, potentially improving outcomes in patients with solid tumors.

Other names: Staphylococcus aureus Site Specific Immunomodulator

Beyond the preview

Go deeper on QBSAU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QBSAU.

Explore the full profile